Mar 11, 2021 / 04:30PM GMT
Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst
Good morning, everybody. Luke Sergott from Barclays. I cover life science tools and diagnostics here. It's with true pleasure that I have Danaher's management of Matt McGrew, and then Matt Gugino and Kelly Brame with us.
So with that, if you guys want to give a little bit of quick intro, then we can get right into questions.
Matthew R. McGrew - Danaher Corporation - CFO & Executive VP
Sure. Yes. Maybe I'll just give a quick update on sort of where we are, what we're seeing. I think the simplest way to say is that we're kind of tracking with what we thought. We've got probably 2 ways to think about it, our base business. I think we -- kind of the modest improvements as expected as the people kind of come back to work and are learning to work in this environment, both in labs as well as elsewhere. I think we have seen -- from a patient volume and maybe a lab opening perspective, I think very consistent with where we stood a couple of weeks ago and, I would say, tracking
Danaher Corp at Barclays Global Healthcare Conference (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers